GlobeNewswire Inc. · Apr 1, 2024
Eiger BioPharmaceuticals Files for Voluntary Chapter 11 Protection
Announces “Stalking Horse” Agreement for the Sale of Zokinvy® (lonafarnib)
EI
NASDAQ · EIGR
Eiger BioPharmaceuticals, Inc.
Healthcare · Biotechnology
$1.73
Up+$0.00 (+0.00%)
Updated Aug 23, 2026, 11:28 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 2.55M
- P/E ratio
- -0.17
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 136.27K
- Avg. volume
- 131.88K
Price performance
EIGR price history
1M range · 0 trading sessions · Daily adjusted prices
EIGR does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest EIGR news
The latest Smart Investors Daily articles mentioning EIGR.
Stock researchCompany · Overview
EIGR research
Overview
Company profile and research snapshot.
Company profile
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $91.80
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 29, 2023 | Citigroup | Buy | — |
| Jun 30, 2023 | Baird | Outperform | — |
| Sep 7, 2022 | BTIG | Buy | — |
| Aug 9, 2021 | Citigroup | Buy | — |
| Apr 3, 2020 | Wedbush | Outperform | — |
News briefing
No generated briefing is available yet.
Benzinga · Jun 30, 2023
Potential Upside For Eiger's Avexitide In Both PBH And CHI Indications: Analyst
Thursday, Eiger BioPharmaceuticals Inc (NASDAQ: EIGR) announced it would focus its development efforts on advancing avexitide in hyperinsulinemic hypoglycemia indications. Following a comprehensive review of programs, the company decided to allocate resources towards the potential of avexitide in treating metabolic diseases, with a primary focus on post-bariatric hypoglycemia (PBH), a condition with significant revenue potential. Baird raised the price target from $3 to $5 with an Outperform rating, citing prudent reprioritization away from virology. It says that it ...Full story available on Benzinga.com
Zacks Investment Research · Nov 1, 2022
Incyte (INCY) Q3 Earnings and Revenues Miss Estimates
Incyte (INCY) delivered earnings and revenue surprises of -16.67% and 2.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
MarketWatch · Oct 5, 2022
Dow falls 300 points after best start to a quarter since 1938
U.S. stocks trade lower on Wednesday as a more cautious tone prevailed following a strong start to the fourth quarter.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
